Clinical Outcomes of Patients With Osteosarcoma Experiencing Relapse or Progression: A Single-institute Experience

• Published in: Journal of pediatric hematology/oncology Vol. 45; no. 3; p. e356
• Main Authors: Umeda, Katsutsugu, Sakamoto, Akio, Noguchi, Takashi, Uchihara, Yoshinori, Kobushi, Hirokazu, Akazawa, Ryo, Ogata, Hideto, Saida, Satoshi, Kato, Itaru, Hiramatsu, Hidefumi, Uto, Megumi, Mizowaki, Takashi, Haga, Hironori, Date, Hiroshi, Okamoto, Takeshi, Watanabe, Kenichiro, Adachi, Souichi, Toguchida, Junya, Matsuda, Shuichi, Takita, Junko
• Format: Journal Article
• Language: English
• Published: United States 01.04.2023
• Subjects: Adult; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bone Neoplasms - pathology; Humans; Neoplasm Recurrence, Local - pathology; Osteosarcoma - drug therapy; Osteosarcoma - pathology; Prognosis; Retrospective Studies
• ISSN: 1536-3678
• DOI: 10.1097/MPH.0000000000002521

Patients with osteosarcoma who experience relapse or progression [R/P] have a poor prognosis. Data from 30 patients who experienced R/P among 59 with a diagnosis of high-grade osteosarcoma, who were younger than 40 years old between 2000 and 2019, were retrospectively analyzed to identify prognostic and therapeutic factors influencing their outcomes. The 5-year overall survival [OS] rates after the last R/P of patients experiencing first [n=30], second [n=14], and third [n=9] R/P were 50.3%, 51.3%, and 46.7%, respectively. Multivariate analysis did not identify any independent risk factors affecting OS. The 5-year PFS rate of the 30 patients after first R/P was 22.4%, and multivariate analysis identified histologic subtype and curative local surgery as independent risk factors influencing PFS. Long [>6 mo] partial response was observed in three patients treated using temozolomide+etoposide, irinotecan+carboplatin, or regorafenib. OS rate in the patients with osteosarcoma experiencing R/P included in this study was markedly higher than that reported previously, mainly due to the surgical total removal of tumors, even after subsequent R/P. The recent establishment of salvage chemotherapy or molecular targeted therapy may also increase survival rates in a subgroup of patients.